Neural network-based real-time prediction of glucose in patients with insulin-dependent diabetes.

abstract：:Several biopharmaceuticals, including insulin and insulin analogs, are, or shortly will be, off-patent, thereby providing an opportunity for companies to attempt to manufacture "copies" commonly referred to as biosimilars and also known as follow-on biologics. Reassurance that such copy biologics are equally safe and ...

journal_title：Diabetes technology & therapeutics

authors： Owens DR,Landgraf W,Schmidt A,Bretzel RG,Kuhlmann MK

更新日期：2012-11-01 00:00:00

abstract：BACKGROUND:Vascular endothelial growth factor (VEGF) is involved in the pathogenesis of diabetic microvascular disease. Most diabetes patients have higher serum levels of ferritin that may participate in diabetic vascular complications through high oxidative stress induced by iron. However, the mechanistic link between...

journal_title：Diabetes technology & therapeutics

authors： Guo L,Jiang F,Tang YT,Si MY,Jiao XY

更新日期：2014-04-01 00:00:00

abstract：BACKGROUND:This study explored the relationships between exogenous insulin requirements and endogenous variables in elderly patients with type 2 diabetes (T2D). SUBJECTS AND METHODS:Patients with T2D 65 years of age or older were enrolled for a short hospitalization period in order to start or change their basal-bolus...

journal_title：Diabetes technology & therapeutics

authors： Nourizadeh-Sedaghati A,Herbin M,Lukas-Croisier C,Novella JL,Delemer B

更新日期：2016-05-01 00:00:00

abstract：BACKGROUND:We aimed to assess the effect of continuous subcutaneous insulin infusion (CSII) therapy in patients with "recalcitrant diabetes" whose glycemia had not been controlled adequately with multiple daily injections of insulin or insulin plus oral hypoglycemic agents. PATIENTS AND METHODS:We retrospectively anal...

journal_title：Diabetes technology & therapeutics

authors： Sudhakaran C,Anjana RM,Rao K,Unnikrishnan R 1st,Suresh T,Mohan V

更新日期：2009-11-01 00:00:00

abstract：BACKGROUND:Persistent use of real-time continuous glucose monitoring (CGM) improves diabetes control in individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D). METHODS:PRECISE II was a nonrandomized, blinded, prospective, single-arm, multicenter study that evaluated the accuracy and safety of the implantable...

journal_title：Diabetes technology & therapeutics

authors： Christiansen MP,Klaff LJ,Brazg R,Chang AR,Levy CJ,Lam D,Denham DS,Atiee G,Bode BW,Walters SJ,Kelley L,Bailey TS

更新日期：2018-03-01 00:00:00

abstract：OBJECTIVE:This study was designed to develop predictive formulas for precise insulin dosing in young children with type 1 diabetes (T1DM). RESEARCH DESIGN AND METHODS:Consecutive 1-year data from a group of 14 young patients (eight girls, six boys) 3.9 ± 0.8 years old with diabetes duration of 2.0 ± 0.8 years, transit...

journal_title：Diabetes technology & therapeutics

authors： Alemzadeh R,Hoffmann RG,Dasgupta M,Parton E

更新日期：2012-05-01 00:00:00

abstract：BACKGROUND:Understanding the effect size, variability, and underlying physiology of the dawn phenomenon is important for next-generation closed-loop control algorithms for type 1 diabetes (T1D). SUBJECTS AND METHODS:We used an iterative protocol design to study 16 subjects with T1D on individualized insulin pump thera...

journal_title：Diabetes technology & therapeutics

authors： Mallad A,Hinshaw L,Dalla Man C,Cobelli C,Basu R,Lingineni R,Carter RE,Kudva YC,Basu A

更新日期：2015-08-01 00:00:00

abstract：BACKGROUND:The purpose of this study is to test the agreement between energy expenditure estimate of the SenseWear(®) Armband Pro3 (SWA) (BodyMedia, Pittsburgh, PA) and the Omron HJ-720 (Omron Healthcare, Kyoto, Japan) step counter with indirect calorimetry (IC) as a gold standard in older individuals with type 1 and t...

journal_title：Diabetes technology & therapeutics

authors： Machač S,Procházka M,Radvanský J,Slabý K

更新日期：2013-05-01 00:00:00

abstract：BACKGROUND:This exploratory study examined the pharmacokinetics and pharmacodynamics of a Bentley Pharmaceuticals, Inc. (North Hampton, NH) proprietary insulin formulation utilizing CPE-215 technology designed for intranasal administration. METHODS:Eight fasting healthy volunteers (four men, four women; body mass inde...

journal_title：Diabetes technology & therapeutics

authors： Leary AC,Stote RM,Breedt HJ,O'Brien J,Buckley B

更新日期：2005-02-01 00:00:00

abstract：BACKGROUND:Continuous glucose monitoring (CGM) has been shown to improve glycemic control and reduce hypoglycemia with consistent use. Youth, however, are unlikely to use CGM consistently. We compared psychological characteristics of youth with type 1 diabetes, their parents, and adults with type 1 diabetes randomized ...

journal_title：Diabetes technology & therapeutics

authors： Markowitz JT,Pratt K,Aggarwal J,Volkening LK,Laffel LM

更新日期：2012-06-01 00:00:00

abstract：OBJECTIVE:To evaluate the safety of in-home use of the MiniMed™ 670G system with SmartGuard™ technology in children with type 1 diabetes (T1D). METHODS:Participants (N = 105, ages 7-13 years, mean age 10.8 ± 1.8 years) were enrolled at nine centers (eight in the United States and one in Israel) and completed a 2-week ...

journal_title：Diabetes technology & therapeutics

authors： Forlenza GP,Pinhas-Hamiel O,Liljenquist DR,Shulman DI,Bailey TS,Bode BW,Wood MA,Buckingham BA,Kaiserman KB,Shin J,Huang S,Lee SW,Kaufman FR

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Implanted insulin pumps using the peritoneal route provide long-term improvement of glucose control compared with subcutaneous insulin therapy in type 1 diabetes (T1D) patients. The stability of insulin preparation is critical for a safe use in implanted pumps. Insuman implantable(®) (400 IU/mL) (Sanofi-Aven...

journal_title：Diabetes technology & therapeutics

authors： Schaepelynck P,Riveline JP,Renard E,Hanaire H,Guerci B,Baillot-Rudoni S,Sola-Gazagnes A,Catargi B,Fontaine P,Millot L,Martin JF,Tachouaft H,Jeandidier N,EVADIAC Group.

更新日期：2014-09-01 00:00:00

abstract：:Chromium (Cr) picolinate (CrPic) is a widely used nutritional supplement for optimal insulin function. A relationship among Cr status, diabetes, and associated pathologies has been established. Virtually all trials using CrPic supplementation for subjects with diabetes have demonstrated beneficial effects. Thirteen of...

journal_title：Diabetes technology & therapeutics

authors： Broadhurst CL,Domenico P

更新日期：2006-12-01 00:00:00

abstract：BACKGROUND:Different reference methods are used for the accuracy assessment of continuous glucose monitoring (CGM) systems. The effect of using venous, arterialized-venous, or capillary reference measurements on CGM accuracy is unclear. METHODS:We evaluated 21 individuals with type 1 diabetes using a capillary calibra...

journal_title：Diabetes technology & therapeutics

authors： Kropff J,van Steen SC,deGraaff P,Chan MW,van Amstel RBE,DeVries JH

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:To examine trimester-specific associations among glycemic variability, fetal growth, and birthweight in pregnancies with type 1 diabetes mellitus (Type 1 DM). METHODS:In this retrospective cohort study of 41 pregnant women with Type 1 DM, we used continuous glucose monitoring (CGM) data to calculate glycemi...

journal_title：Diabetes technology & therapeutics

authors： Mulla BM,Noor N,James-Todd T,Isganaitis E,Takoudes TC,Curran A,Warren CE,O'Brien KE,Brown FM

更新日期：2018-06-01 00:00:00

abstract：: Background: The financial strain of type 1 diabetes on the United States health care system, patients, and employers underscores the importance of developing novel treatments for the disease. This study estimated the lifetime economic burden attributable to type 1 diabetes...

journal_title：Diabetes technology & therapeutics

authors： Sussman M,Benner J,Haller MJ,Rewers M,Griffiths R

更新日期：2020-02-01 00:00:00

abstract：BACKGROUND:The present study evaluated the efficacy of biphasic human insulin 30 (BHI 30) in type 2 diabetes patients who had failed in therapy with two or more oral antidiabetes drugs (OADs). METHODS:This open-label, nonrandomized, 4-month, multicenter, clinical observational study was conducted in Shanghai, China. A...

journal_title：Diabetes technology & therapeutics

authors： Gu Y,Hou X,Zhang L,Pan J,Cai Q,Bao Y,Jia W

更新日期：2012-03-01 00:00:00

abstract：BACKGROUND:Little information is available regarding glucose fluctuations in postprandial states and during the oral glucose tolerance test (OGTT) in Japanese people with normal glucose tolerance (NGT). METHODS:Glucose profiles of 27 Japanese people were measured for 4 days by using continuous glucose monitoring. A 75...

journal_title：Diabetes technology & therapeutics

authors： Tsujino D,Nishimura R,Taki K,Miyashita Y,Morimoto A,Tajima N

更新日期：2009-07-01 00:00:00

abstract：BACKGROUND:Performance of continuous glucose monitors (CGMs) may be lower when glucose levels are changing rapidly, such as occurs during physical activity. Our aim was to evaluate accuracy of a current-generation CGM during moderate-intensity exercise in type 1 diabetes (T1D) pregnancy. SUBJECTS AND METHODS:As part o...

journal_title：Diabetes technology & therapeutics

authors： Kumareswaran K,Elleri D,Allen JM,Caldwell K,Nodale M,Wilinska ME,Amiel SA,Hovorka R,Murphy HR

更新日期：2013-03-01 00:00:00

abstract：:On May 26, 1976, the Food and Drug Administration (FDA) began implementing the Medical Device Amendments to the Federal Food Drug and Cosmetic Act. These amendments give FDA specific authority to regulate "medical devices." Additional authority was provided in the Safe Medical Devices Act of 1990. The pathways to get ...

journal_title：Diabetes technology & therapeutics

authors： Gutman S,Bernhardt P,Pinkos A,Moxey-Mims M,Knott T,Cooper J

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:Type 2 diabetes is an individual health challenge requiring ongoing self-management. Remote patient reporting of relevant health parameters and linked automated feedback via mobile telephone have potential to strengthen self-management and improve outcomes. This research involved development and evaluation o...

journal_title：Diabetes technology & therapeutics

authors： Orsama AL,Lähteenmäki J,Harno K,Kulju M,Wintergerst E,Schachner H,Stenger P,Leppänen J,Kaijanranta H,Salaspuro V,Fisher WA

更新日期：2013-08-01 00:00:00

abstract：:Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are highly effective at lowering hemoglobin A1c (HbA1c) and facilitating weight loss. Four agents in the GLP-1 RA class, albiglutide, liraglutide, dulaglutide, and semaglutide, also have cardioprotective effects. However, subcutaneous administration of these agents...

journal_title：Diabetes technology & therapeutics

authors： Bucheit JD,Pamulapati LG,Carter N,Malloy K,Dixon DL,Sisson EM

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:This study evaluated whether education and use of the advanced meter features of the CONTOUR(®) (Bayer HealthCare LLC, Diabetes Care, Tarrytown, NY) blood glucose monitoring system (BGMS) affect the frequency and pattern of blood glucose testing in insulin-using subjects with diabetes who routinely perform s...

journal_title：Diabetes technology & therapeutics

authors： Bergenstal RM,Bode BW,Tamler R,Trence DL,Stenger P,Schachner HC,Fullam J,Pardo S,Kohut T,Fisher WA

更新日期：2012-10-01 00:00:00

abstract：:Treatments for type 1 diabetes have advanced significantly over recent years. There are now multiple hybrid closed-loop systems commercially available and additional systems are in development. Challenges remain, however. This review outlines the recent advances in closed-loop systems and outlines the remaining challe...

journal_title：Diabetes technology & therapeutics

authors： Jackson M,Castle JR

更新日期：2020-07-01 00:00:00

abstract：OBJECTIVE:This study assessed the association of serum adiponectin with carotid intimal medial thickness (IMT) in Asian Indians with different grades of glucose intolerance. METHODS:Subjects with normal glucose tolerance (NGT) (n = 520), impaired glucose tolerance (IGT) (n = 115), and type 2 diabetes mellitus (T2DM) (...

journal_title：Diabetes technology & therapeutics

authors： Gokulakrishnan K,Indulekha K,Ganesan S,Anuradha S,Mohan V

更新日期：2010-02-01 00:00:00

abstract：:The foreign body capsule that forms around implanted devices such as glucose sensors is hypovascular and has limited permeability to glucose. Such a capsule may function better if well vascularized. We hypothesized that capsular vascularization achieved by local release of vascular endothelial growth factor (VEGF) wou...

journal_title：Diabetes technology & therapeutics

authors： Ward WK,Wood MD,Casey HM,Quinn MJ,Federiuk IF

更新日期：2004-04-01 00:00:00

abstract：BACKGROUND:The junction of telemedicine home monitoring with multifaceted disease management programs seems nowadays a promising direction to combine the need for an intensive approach to deal with diabetes and the pressure to contain the costs of the interventions. Several projects in the European Union and the United...

journal_title：Diabetes technology & therapeutics

authors： Bellazzi R,Arcelloni M,Ferrari P,Decata P,Hernando ME,García A,Gazzaruso C,Gómez EJ,Larizza C,Fratino P,Stefanelli M

更新日期：2004-10-01 00:00:00

abstract：UNLABELLED:Abstract Objective: Controlled inpatient studies on the effects of food, physical activity (PA), and insulin dosing on glucose excursions exist, but such outpatient data are limited. We report here outpatient data on glucose excursions and its key determinants over 5 days in 30 adolescents with type 1 diab...

journal_title：Diabetes technology & therapeutics

authors： Maahs DM,Mayer-Davis E,Bishop FK,Wang L,Mangan M,McMurray RG

更新日期：2012-08-01 00:00:00

abstract：BACKGROUND:Continuous glucose monitoring (CGM) has been shown to be a valuable tool to improve glycemic control in patients with diabetes. The objective of this pilot study was to develop and implement CGM in an existing diabetes clinic for low-income patients on multiple daily injections. SUBJECTS AND METHODS:This wa...

journal_title：Diabetes technology & therapeutics

authors： Sequeira PA,Montoya L,Ruelas V,Xing D,Chen V,Beck R,Peters AL

更新日期：2013-10-01 00:00:00

abstract：BACKGROUND:This study assessed the feasibility of a portable bihormonal closed-loop system at home. SUBJECTS AND METHODS:Sixteen pump-treated patients with type 1 diabetes received 48 h of closed-loop therapy with a telemonitored insulin- and glucagon-delivering closed-loop system and 48 h of patient-managed open-loop...

journal_title：Diabetes technology & therapeutics

authors： van Bon AC,Luijf YM,Koebrugge R,Koops R,Hoekstra JB,DeVries JH

更新日期：2014-03-01 00:00:00